David Esposito, President and CEO of Armune BioScience, presented a plan to develop and commercialize high value cancer diagnostic and prognostic tests, to “The Pulse of Progress 2015 Health-Tech Forum,” while at the Holiday Inn of Midland Michigan, Wednesday, April 8th. He shared the company’s mission, scope of the current situation specifically connected to prostate cancer, and began to cover development and validation of Armune’s process, and its product, “Apifiny.”